Abstract
Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wardley, A., Jayson, G., Goldsmith, D. et al. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 78, 774–776 (1998). https://doi.org/10.1038/bjc.1998.577
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.577
- Springer Nature Limited
This article is cited by
-
How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis
Clinical and Experimental Nephrology (2011)
-
Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report
Journal of Medical Case Reports (2010)
-
Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation
Clinical and Experimental Nephrology (2009)
-
A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study
Bone Marrow Transplantation (2004)
-
Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report
Bone Marrow Transplantation (2000)